Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briakinumab Phase 2b in Moderate to Severe Crohn's Disease
NCT00562887Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Nov 2007
- Primary completion
- Apr 2010
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of briakinumab in Crohn's disease, sponsored by Abbott Laboratories. Started Nov 2007; status: terminated.
02
Drugs
briakinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00562887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562887.